Global Mucin 1 Market

Mucin 1 Comprehensive Study by Type (TG-4010, GO-2032c, ImMucin, BI-1361849, Others), Application (Prostate Cancer, Breast Cancer, Colon Cancer, Ovarian Cancer, Others) Players and Region - Global Market Outlook to 2027

Mucin 1 Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Mucin 1
Mucin 1 is also known as polymorphic epithelial mucin (PEM), Tumor-associated (EMA) PUM, PEMT, Krebs von den Lungen-6 (KL-6), CD antigen CD227, Episialin, and H23AG. It is a glycoprotein with extensive O-linked glycosylation of its extracellular domain. Mucins line the apical surface of epithelial cells in the lungs, intestines, stomach, eyes and several other organs. Mucins defend the body from infection by pathogen binding to oligosaccharides in the extracellular domain, inhibiting the pathogen from reaching the cell surface. Except for protective function by binding to pathogens, Mucin 1 also functions in a cell signalling capacity. Overexpression of MUC1 is often associated with breast, colon, ovarian, lung and pancreatic cancers.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


The key manufacturers are targeting the innovations of the products with better quality, and better technical characteristics, and also assist in providing and humanizing the after-sale service to the consumers. The key players are probable to keep a stronghold on the market over the anticipated period. The key players are accepting strategic decisions and are thinking about mergers and acquisitions in order to maintain their presence in the market Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Mucin 1 market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Akshaya Bio Inc. (Canada), Bavarian Nordic A/S (Denmark), Boehringer Ingelheim GmbH (Germany), Etubics Corp (United States), GeoVax Labs Inc. (United States), Merck KGaA (Germany), Minerva Biotechnologies Corp (United States), Transgene SA (France), Vaxil Bio Therapeutics Ltd (Canada) and AcroBiosystems (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Mucin 1 market by Type (TG-4010, GO-2032c, ImMucin, BI-1361849 and Others), Application (Prostate Cancer, Breast Cancer, Colon Cancer, Ovarian Cancer and Others) and Region.

On the basis of geography, the market of Mucin 1 has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
In 2020, Tmunity Therapeutics Inc. announced the phase 1 clinical trial of CART-TnMUC1-01 with the Tn/STn glycoform of mucin 1 in patients with TnMUC1-positive advanced cancers. CART-TnMUC1-01 therapy was developed by the University of Pennsylvania team in order to develop and expand its innovative cell therapies portfolio for high unmet needs in solid tumors.
In November 2021, GeoVax Labs, Inc., a leading biotech company receives notice of allowance for cancer vaccine patents from the U.S. Patent and Trademark Office. The patent covers GeoVax’s vector platform and GeoVax’s Mucin 1 tumor-associated antigen immunotherapy. The company uses the MVA-VLP vaccine platform to express abnormal, aberrantly glycosylated forms of the cell surface-associated MUC1 protein.


Market Drivers
  • The Rising Prevalence of Cancer Worldwide Fueling the Growth of the Market

Opportunities
  • Future Research & Development Activities Is Expected to Open Lucrative Opportunities for the Market

Restraints
  • Stringent Government Regulations


Key Target Audience
Mucin 1 Manufacturers, Mucin 1 Traders/Distributors, Mucin 1 Importer/Exporter, Regulatory & Government Bodies, End Users and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • TG-4010
  • GO-2032c
  • ImMucin
  • BI-1361849
  • Others
By Application
  • Prostate Cancer
  • Breast Cancer
  • Colon Cancer
  • Ovarian Cancer
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Rising Prevalence of Cancer Worldwide Fueling the Growth of the Market
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Mucin 1, by Type, Application and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Mucin 1 (Value)
      • 5.2.1. Global Mucin 1 by: Type (Value)
        • 5.2.1.1. TG-4010
        • 5.2.1.2. GO-2032c
        • 5.2.1.3. ImMucin
        • 5.2.1.4. BI-1361849
        • 5.2.1.5. Others
      • 5.2.2. Global Mucin 1 by: Application (Value)
        • 5.2.2.1. Prostate Cancer
        • 5.2.2.2. Breast Cancer
        • 5.2.2.3. Colon Cancer
        • 5.2.2.4. Ovarian Cancer
        • 5.2.2.5. Others
      • 5.2.3. Global Mucin 1 Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Mucin 1: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Akshaya Bio Inc. (Canada)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bavarian Nordic A/S (Denmark)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Boehringer Ingelheim GmbH (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Etubics Corp (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GeoVax Labs Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck KGaA (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Minerva Biotechnologies Corp (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Transgene SA (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Vaxil Bio Therapeutics Ltd (Canada)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AcroBiosystems (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Mucin 1 Sale, by Type, Application and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Mucin 1 (Value)
      • 7.2.1. Global Mucin 1 by: Type (Value)
        • 7.2.1.1. TG-4010
        • 7.2.1.2. GO-2032c
        • 7.2.1.3. ImMucin
        • 7.2.1.4. BI-1361849
        • 7.2.1.5. Others
      • 7.2.2. Global Mucin 1 by: Application (Value)
        • 7.2.2.1. Prostate Cancer
        • 7.2.2.2. Breast Cancer
        • 7.2.2.3. Colon Cancer
        • 7.2.2.4. Ovarian Cancer
        • 7.2.2.5. Others
      • 7.2.3. Global Mucin 1 Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Mucin 1: by Type(USD Million)
  • Table 2. Mucin 1 TG-4010 , by Region USD Million (2016-2021)
  • Table 3. Mucin 1 GO-2032c , by Region USD Million (2016-2021)
  • Table 4. Mucin 1 ImMucin , by Region USD Million (2016-2021)
  • Table 5. Mucin 1 BI-1361849 , by Region USD Million (2016-2021)
  • Table 6. Mucin 1 Others , by Region USD Million (2016-2021)
  • Table 7. Mucin 1: by Application(USD Million)
  • Table 8. Mucin 1 Prostate Cancer , by Region USD Million (2016-2021)
  • Table 9. Mucin 1 Breast Cancer , by Region USD Million (2016-2021)
  • Table 10. Mucin 1 Colon Cancer , by Region USD Million (2016-2021)
  • Table 11. Mucin 1 Ovarian Cancer , by Region USD Million (2016-2021)
  • Table 12. Mucin 1 Others , by Region USD Million (2016-2021)
  • Table 13. South America Mucin 1, by Country USD Million (2016-2021)
  • Table 14. South America Mucin 1, by Type USD Million (2016-2021)
  • Table 15. South America Mucin 1, by Application USD Million (2016-2021)
  • Table 16. Brazil Mucin 1, by Type USD Million (2016-2021)
  • Table 17. Brazil Mucin 1, by Application USD Million (2016-2021)
  • Table 18. Argentina Mucin 1, by Type USD Million (2016-2021)
  • Table 19. Argentina Mucin 1, by Application USD Million (2016-2021)
  • Table 20. Rest of South America Mucin 1, by Type USD Million (2016-2021)
  • Table 21. Rest of South America Mucin 1, by Application USD Million (2016-2021)
  • Table 22. Asia Pacific Mucin 1, by Country USD Million (2016-2021)
  • Table 23. Asia Pacific Mucin 1, by Type USD Million (2016-2021)
  • Table 24. Asia Pacific Mucin 1, by Application USD Million (2016-2021)
  • Table 25. China Mucin 1, by Type USD Million (2016-2021)
  • Table 26. China Mucin 1, by Application USD Million (2016-2021)
  • Table 27. Japan Mucin 1, by Type USD Million (2016-2021)
  • Table 28. Japan Mucin 1, by Application USD Million (2016-2021)
  • Table 29. India Mucin 1, by Type USD Million (2016-2021)
  • Table 30. India Mucin 1, by Application USD Million (2016-2021)
  • Table 31. South Korea Mucin 1, by Type USD Million (2016-2021)
  • Table 32. South Korea Mucin 1, by Application USD Million (2016-2021)
  • Table 33. Taiwan Mucin 1, by Type USD Million (2016-2021)
  • Table 34. Taiwan Mucin 1, by Application USD Million (2016-2021)
  • Table 35. Australia Mucin 1, by Type USD Million (2016-2021)
  • Table 36. Australia Mucin 1, by Application USD Million (2016-2021)
  • Table 37. Rest of Asia-Pacific Mucin 1, by Type USD Million (2016-2021)
  • Table 38. Rest of Asia-Pacific Mucin 1, by Application USD Million (2016-2021)
  • Table 39. Europe Mucin 1, by Country USD Million (2016-2021)
  • Table 40. Europe Mucin 1, by Type USD Million (2016-2021)
  • Table 41. Europe Mucin 1, by Application USD Million (2016-2021)
  • Table 42. Germany Mucin 1, by Type USD Million (2016-2021)
  • Table 43. Germany Mucin 1, by Application USD Million (2016-2021)
  • Table 44. France Mucin 1, by Type USD Million (2016-2021)
  • Table 45. France Mucin 1, by Application USD Million (2016-2021)
  • Table 46. Italy Mucin 1, by Type USD Million (2016-2021)
  • Table 47. Italy Mucin 1, by Application USD Million (2016-2021)
  • Table 48. United Kingdom Mucin 1, by Type USD Million (2016-2021)
  • Table 49. United Kingdom Mucin 1, by Application USD Million (2016-2021)
  • Table 50. Netherlands Mucin 1, by Type USD Million (2016-2021)
  • Table 51. Netherlands Mucin 1, by Application USD Million (2016-2021)
  • Table 52. Rest of Europe Mucin 1, by Type USD Million (2016-2021)
  • Table 53. Rest of Europe Mucin 1, by Application USD Million (2016-2021)
  • Table 54. MEA Mucin 1, by Country USD Million (2016-2021)
  • Table 55. MEA Mucin 1, by Type USD Million (2016-2021)
  • Table 56. MEA Mucin 1, by Application USD Million (2016-2021)
  • Table 57. Middle East Mucin 1, by Type USD Million (2016-2021)
  • Table 58. Middle East Mucin 1, by Application USD Million (2016-2021)
  • Table 59. Africa Mucin 1, by Type USD Million (2016-2021)
  • Table 60. Africa Mucin 1, by Application USD Million (2016-2021)
  • Table 61. North America Mucin 1, by Country USD Million (2016-2021)
  • Table 62. North America Mucin 1, by Type USD Million (2016-2021)
  • Table 63. North America Mucin 1, by Application USD Million (2016-2021)
  • Table 64. United States Mucin 1, by Type USD Million (2016-2021)
  • Table 65. United States Mucin 1, by Application USD Million (2016-2021)
  • Table 66. Canada Mucin 1, by Type USD Million (2016-2021)
  • Table 67. Canada Mucin 1, by Application USD Million (2016-2021)
  • Table 68. Mexico Mucin 1, by Type USD Million (2016-2021)
  • Table 69. Mexico Mucin 1, by Application USD Million (2016-2021)
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Mucin 1: by Type(USD Million)
  • Table 81. Mucin 1 TG-4010 , by Region USD Million (2022-2027)
  • Table 82. Mucin 1 GO-2032c , by Region USD Million (2022-2027)
  • Table 83. Mucin 1 ImMucin , by Region USD Million (2022-2027)
  • Table 84. Mucin 1 BI-1361849 , by Region USD Million (2022-2027)
  • Table 85. Mucin 1 Others , by Region USD Million (2022-2027)
  • Table 86. Mucin 1: by Application(USD Million)
  • Table 87. Mucin 1 Prostate Cancer , by Region USD Million (2022-2027)
  • Table 88. Mucin 1 Breast Cancer , by Region USD Million (2022-2027)
  • Table 89. Mucin 1 Colon Cancer , by Region USD Million (2022-2027)
  • Table 90. Mucin 1 Ovarian Cancer , by Region USD Million (2022-2027)
  • Table 91. Mucin 1 Others , by Region USD Million (2022-2027)
  • Table 92. South America Mucin 1, by Country USD Million (2022-2027)
  • Table 93. South America Mucin 1, by Type USD Million (2022-2027)
  • Table 94. South America Mucin 1, by Application USD Million (2022-2027)
  • Table 95. Brazil Mucin 1, by Type USD Million (2022-2027)
  • Table 96. Brazil Mucin 1, by Application USD Million (2022-2027)
  • Table 97. Argentina Mucin 1, by Type USD Million (2022-2027)
  • Table 98. Argentina Mucin 1, by Application USD Million (2022-2027)
  • Table 99. Rest of South America Mucin 1, by Type USD Million (2022-2027)
  • Table 100. Rest of South America Mucin 1, by Application USD Million (2022-2027)
  • Table 101. Asia Pacific Mucin 1, by Country USD Million (2022-2027)
  • Table 102. Asia Pacific Mucin 1, by Type USD Million (2022-2027)
  • Table 103. Asia Pacific Mucin 1, by Application USD Million (2022-2027)
  • Table 104. China Mucin 1, by Type USD Million (2022-2027)
  • Table 105. China Mucin 1, by Application USD Million (2022-2027)
  • Table 106. Japan Mucin 1, by Type USD Million (2022-2027)
  • Table 107. Japan Mucin 1, by Application USD Million (2022-2027)
  • Table 108. India Mucin 1, by Type USD Million (2022-2027)
  • Table 109. India Mucin 1, by Application USD Million (2022-2027)
  • Table 110. South Korea Mucin 1, by Type USD Million (2022-2027)
  • Table 111. South Korea Mucin 1, by Application USD Million (2022-2027)
  • Table 112. Taiwan Mucin 1, by Type USD Million (2022-2027)
  • Table 113. Taiwan Mucin 1, by Application USD Million (2022-2027)
  • Table 114. Australia Mucin 1, by Type USD Million (2022-2027)
  • Table 115. Australia Mucin 1, by Application USD Million (2022-2027)
  • Table 116. Rest of Asia-Pacific Mucin 1, by Type USD Million (2022-2027)
  • Table 117. Rest of Asia-Pacific Mucin 1, by Application USD Million (2022-2027)
  • Table 118. Europe Mucin 1, by Country USD Million (2022-2027)
  • Table 119. Europe Mucin 1, by Type USD Million (2022-2027)
  • Table 120. Europe Mucin 1, by Application USD Million (2022-2027)
  • Table 121. Germany Mucin 1, by Type USD Million (2022-2027)
  • Table 122. Germany Mucin 1, by Application USD Million (2022-2027)
  • Table 123. France Mucin 1, by Type USD Million (2022-2027)
  • Table 124. France Mucin 1, by Application USD Million (2022-2027)
  • Table 125. Italy Mucin 1, by Type USD Million (2022-2027)
  • Table 126. Italy Mucin 1, by Application USD Million (2022-2027)
  • Table 127. United Kingdom Mucin 1, by Type USD Million (2022-2027)
  • Table 128. United Kingdom Mucin 1, by Application USD Million (2022-2027)
  • Table 129. Netherlands Mucin 1, by Type USD Million (2022-2027)
  • Table 130. Netherlands Mucin 1, by Application USD Million (2022-2027)
  • Table 131. Rest of Europe Mucin 1, by Type USD Million (2022-2027)
  • Table 132. Rest of Europe Mucin 1, by Application USD Million (2022-2027)
  • Table 133. MEA Mucin 1, by Country USD Million (2022-2027)
  • Table 134. MEA Mucin 1, by Type USD Million (2022-2027)
  • Table 135. MEA Mucin 1, by Application USD Million (2022-2027)
  • Table 136. Middle East Mucin 1, by Type USD Million (2022-2027)
  • Table 137. Middle East Mucin 1, by Application USD Million (2022-2027)
  • Table 138. Africa Mucin 1, by Type USD Million (2022-2027)
  • Table 139. Africa Mucin 1, by Application USD Million (2022-2027)
  • Table 140. North America Mucin 1, by Country USD Million (2022-2027)
  • Table 141. North America Mucin 1, by Type USD Million (2022-2027)
  • Table 142. North America Mucin 1, by Application USD Million (2022-2027)
  • Table 143. United States Mucin 1, by Type USD Million (2022-2027)
  • Table 144. United States Mucin 1, by Application USD Million (2022-2027)
  • Table 145. Canada Mucin 1, by Type USD Million (2022-2027)
  • Table 146. Canada Mucin 1, by Application USD Million (2022-2027)
  • Table 147. Mexico Mucin 1, by Type USD Million (2022-2027)
  • Table 148. Mexico Mucin 1, by Application USD Million (2022-2027)
  • Table 149. Research Programs/Design for This Report
  • Table 150. Key Data Information from Secondary Sources
  • Table 151. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Mucin 1: by Type USD Million (2016-2021)
  • Figure 5. Global Mucin 1: by Application USD Million (2016-2021)
  • Figure 6. South America Mucin 1 Share (%), by Country
  • Figure 7. Asia Pacific Mucin 1 Share (%), by Country
  • Figure 8. Europe Mucin 1 Share (%), by Country
  • Figure 9. MEA Mucin 1 Share (%), by Country
  • Figure 10. North America Mucin 1 Share (%), by Country
  • Figure 11. Global Mucin 1 share by Players 2021 (%)
  • Figure 12. Global Mucin 1 share by Players (Top 3) 2021(%)
  • Figure 13. Global Mucin 1 share by Players (Top 5) 2021(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Akshaya Bio Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 16. Akshaya Bio Inc. (Canada) Revenue: by Geography 2021
  • Figure 17. Bavarian Nordic A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 18. Bavarian Nordic A/S (Denmark) Revenue: by Geography 2021
  • Figure 19. Boehringer Ingelheim GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 20. Boehringer Ingelheim GmbH (Germany) Revenue: by Geography 2021
  • Figure 21. Etubics Corp (United States) Revenue, Net Income and Gross profit
  • Figure 22. Etubics Corp (United States) Revenue: by Geography 2021
  • Figure 23. GeoVax Labs Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. GeoVax Labs Inc. (United States) Revenue: by Geography 2021
  • Figure 25. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Merck KGaA (Germany) Revenue: by Geography 2021
  • Figure 27. Minerva Biotechnologies Corp (United States) Revenue, Net Income and Gross profit
  • Figure 28. Minerva Biotechnologies Corp (United States) Revenue: by Geography 2021
  • Figure 29. Transgene SA (France) Revenue, Net Income and Gross profit
  • Figure 30. Transgene SA (France) Revenue: by Geography 2021
  • Figure 31. Vaxil Bio Therapeutics Ltd (Canada) Revenue, Net Income and Gross profit
  • Figure 32. Vaxil Bio Therapeutics Ltd (Canada) Revenue: by Geography 2021
  • Figure 33. AcroBiosystems (United States) Revenue, Net Income and Gross profit
  • Figure 34. AcroBiosystems (United States) Revenue: by Geography 2021
  • Figure 35. Global Mucin 1: by Type USD Million (2022-2027)
  • Figure 36. Global Mucin 1: by Application USD Million (2022-2027)
  • Figure 37. South America Mucin 1 Share (%), by Country
  • Figure 38. Asia Pacific Mucin 1 Share (%), by Country
  • Figure 39. Europe Mucin 1 Share (%), by Country
  • Figure 40. MEA Mucin 1 Share (%), by Country
  • Figure 41. North America Mucin 1 Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Akshaya Bio Inc. (Canada)
  • Bavarian Nordic A/S (Denmark)
  • Boehringer Ingelheim GmbH (Germany)
  • Etubics Corp (United States)
  • GeoVax Labs Inc. (United States)
  • Merck KGaA (Germany)
  • Minerva Biotechnologies Corp (United States)
  • Transgene SA (France)
  • Vaxil Bio Therapeutics Ltd (Canada)
  • AcroBiosystems (United States)
Select User Access Type

Key Highlights of Report


Jun 2022 147 Pages 93 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Mucin 1 Market Quantitative research analysis
Global Mucin 1 Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Akshaya Bio Inc. (Canada), Bavarian Nordic A/S (Denmark), Boehringer Ingelheim GmbH (Germany), Etubics Corp (United States), GeoVax Labs Inc. (United States), Merck KGaA (Germany), Minerva Biotechnologies Corp (United States), Transgene SA (France), Vaxil Bio Therapeutics Ltd (Canada) and AcroBiosystems (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Mucin 1 Market Report?

Have a Query? Click Here

Other Related Reports

Protein Production Comprehensive Study by Type (Prokaryotic Systems, Mammalian Cell Systems, Yeast Cell Systems, Insect Cell Systems, Cell-Free Systems, Algal-Based Systems, Others), Application (Com...
$ 3750
Recombinant Human EGF Comprehensive Study by Application (Pharmaceuticals, Cosmetics, Others), Category (Heparin-binding EGF-like growth factor (HB-EGF), Amphiregulin (AR), Epiregulin (EPR), Transfor...
$ 3750
Genetic Ancestry Testing Comprehensive Study by Type (Y Chromosome Testing, Mitochondrial DNA Testing, Single Nucleotide Polymorphism Testing), Service (Online Testing, Offline Testing) Players and R...
$ 3500
Ion Indicator Comprehensive Study by Type (Zinc Indicators, Calcium Indicators, Sodium Indicators, Potassium Indicators, Chloride Indicators, Membrane Potential Indicators, PH Indicators), Applicatio...
$ 3350
Cryogenic Storage Chest Freezers Comprehensive Study by Type (-20°C~-80°C, <-80°C), Application (Research Institutes and Universities, Life sciences and Pharmaceuticals, Others), Distribution Channel...
$ 3350
Cellular Health Assays Comprehensive Study by Type (ADME Tox Assays, 3D Cell Culture, Apoptosis Assays, Autophagy Detection, Inflammation Assays, Others), Application (Biomedical Research, Drug-disco...
$ 3650